Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters.
Walker AL
,
Franke RM
,
Sparreboom A
,
Ware RE
.
???displayArticle.abstract???
Hydroxyurea has proven laboratory and clinical therapeutic benefits for sickle cell anemia and other diseases, yet many questions remain about its in vivo pharmacokinetic and pharmacodynamic profiles. Previous reports suggest that hydroxyurea passively diffuses across cells, but its observed rapid absorption and distribution are more consistent with facilitated or active transport. We investigated the potential role of solute carrier (SLC) transporters in cellular uptake and accumulation of hydroxyurea. Passive diffusion of hydroxyurea across cell membranes was determined using the parallel artificial membrane permeability assay. SLC transporter screens were conducted using in vitro intracellular drug accumulation and transcellular transport assays in cell lines and oocytes overexpressing SLC transporters. Gene expression of SLC transporters was measured by real-time polymerase chain reaction in human tissues and cell lines. Hydroxyurea had minimal diffusion across a lipid bilayer but was a substrate for five different SLC transporters belonging to the organic cation/carnitine transporters and organic anion transporting polypeptides (OATP) families of transporters and urea transporters A and B. Further characterization of hydroxyurea transport revealed that cellular uptake by OATP1B3 is time- and temperature-dependent and inhibited by known substrates of OATP1B3. Urea transporters A and B are expressed differentially in human tissues and erythroid cells, and transport hydroxyurea bidirectionally via facilitated diffusion. These studies provide new insight into drug transport proteins that may be involved in the in vivo absorption, cellular distribution, and elimination of hydroxyurea. Elucidation of hydroxyurea transcellular movement should improve our understanding of its pharmacokinetics and pharmacodynamics, and may help explain some of the interpatient drug variability observed in patients with sickle cell anemia.
Adamson,
The distribution, excretion and metabolism of hydroxyurea-C14.
1965, Pubmed
Adamson,
The distribution, excretion and metabolism of hydroxyurea-C14.
1965,
Pubmed
Brahm,
Urea permeability of human red cells.
1983,
Pubmed
Charache,
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
1995,
Pubmed
Charache,
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
1992,
Pubmed
Cokic,
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.
2003,
Pubmed
Dover,
Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production.
1986,
Pubmed
Elford,
Effect of hydroxyurea on ribonucleotide reductase.
1968,
Pubmed
Evered,
Transport characteristics of two carcinostatic compounds, hydroxyurea and hadacidin, with rat small intestine.
1972,
Pubmed
Finkelstein,
Water and nonelectrolyte permeability of lipid bilayer membranes.
1976,
Pubmed
Grover,
Effects of drug transporters on volume of distribution.
2009,
Pubmed
Gwilt,
Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients.
2003,
Pubmed
Kalliokoski,
Impact of OATP transporters on pharmacokinetics.
2009,
Pubmed
Kerb,
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
2006,
Pubmed
Kinney,
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
1999,
Pubmed
Kitamura,
Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans.
2008,
Pubmed
Koepsell,
Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications.
2007,
Pubmed
Levin,
Crystal structure of a bacterial homologue of the kidney urea transporter.
2009,
Pubmed
,
Xenbase
Morgan,
Evidence that the antitumor agent hydroxyurea enters mammalian cells by a diffusion mechanism.
1986,
Pubmed
Oostendorp,
The biological and clinical role of drug transporters at the intestinal barrier.
2009,
Pubmed
Platt,
Hydroxyurea for the treatment of sickle cell anemia.
2008,
Pubmed
Rodriguez,
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
1998,
Pubmed
Shayakul,
The SLC14 gene family of urea transporters.
2004,
Pubmed
Snyder,
The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea.
1984,
Pubmed
Stevens,
Hydroxyurea: an overview.
1999,
Pubmed
Stewart,
Ubiquitination regulates the plasma membrane expression of renal UT-A urea transporters.
2008,
Pubmed
Sylvester,
Excretion of hydroxyurea into milk.
1987,
Pubmed
Tagger,
Hydroxy[14C]urea uptake by normal and transformed human cells: evidence for a mechanism of passive diffusion.
1987,
Pubmed
Tsukaguchi,
Cloning and characterization of the urea transporter UT3: localization in rat kidney and testis.
1997,
Pubmed
,
Xenbase
Wagner,
Urea transporters are distributed in endothelial cells and mediate inhibition of L-arginine transport.
2002,
Pubmed
Ware,
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
2002,
Pubmed
Ware,
How I use hydroxyurea to treat young patients with sickle cell anemia.
2010,
Pubmed
Wohnsland,
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
2001,
Pubmed
Xia,
Interactions of cyclosporin a with breast cancer resistance protein.
2007,
Pubmed
You,
Cloning and characterization of the vasopressin-regulated urea transporter.
1993,
Pubmed
,
Xenbase
Zhao,
Comparative transport efficiencies of urea analogues through urea transporter UT-B.
2007,
Pubmed
Zimmerman,
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
2004,
Pubmed
de Montalembert,
Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease.
2006,
Pubmed